Cyclophosphamide, an immunosuppressant administered either orally or intravenously, is an antineoplastic prodrug metabolized by P450 enzymes to phosphoramide mustard and acrolein which in turn alkylate DNA and proteins, respectively [1]. It is widely used in the treatment of chronic lymphocytic leukemia, lymphomas, and soft tissue and osteogenic sarcomas. [2]

Cyclophosphamide was shown to induce apoptosis in wt 9L gliosarcoma cells that did not express Bcl-2. Bcl-2 diminishes cyclophosphamide's cytotoxic activity, but not cytostatic activity. [1]